Passage Bio Inc (PASG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.29M
Last updated: Nov 17, 2026 at 4:10 PM ET
Passage Bio Inc (PASG) Statistics
Passage Bio (PASG) has a market cap of $13.29M. It holds $20.16M more cash than debt, 151.70% of its market cap.
Total Valuation
| Market Cap | $13.29M |
|---|---|
| Latest price (Nov 17, 2026) | $4.22 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 52.32% over 52 weeks and trades 3.18% above its 50-day average.
| Beta (1Y) | 1.96 |
|---|---|
| 52-Week Change | -52.32% |
| 1-Month Change | +17.88% |
| 3-Month Change | -6.43% |
| 6-Month Change | -16.93% |
| 5-Year Change | -98.02% |
| Total Return (1Y) | -52.32% |
| Total Return (3Y CAGR) | -29.41% |
| Total Return (5Y CAGR) | -51.93% |
| Return vs SPY (1Y) | -62.03% |
| Max Drawdown (1Y) | -83.27% |
| Max Drawdown (3Y) | -90.40% |
| Sharpe Ratio (1Y) | -0.60 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $4.09 |
| 200-Day Average | $5.74 |
| 52-Week Range | $3.29 to $20.00 |
| RSI (14 Days) | 58.5 |
| Average Volume (20 Days) | 16.44K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.00x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.00x |
|---|---|
| Quick Ratio | 1.00x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -66164.00% and return on assets is -159.10% over the last 12 months.
| Return on Equity (ROE) | -66164.00% |
|---|---|
| Return on Assets (ROA) | -159.10% |
| Return on Capital Employed (ROCE) | -66164.00% |
| ROA (5Y Average) | -62.45% |
Scores
PASG has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$177.00K |
| Operating Income | -$35.31M |
| Pretax Income | -$33.08M |
| Net Income | -$33.08M |
| EBITDA | -$32.75M |
| EBIT | -$33.08M |
| Reported EPS (TTM) | -$10.36 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 0.24% of the $20.79M in total assets.
| Cash and Equivalents | $20.16M |
|---|---|
| Total Debt | $0 |
| Net Cash | $20.16M |
| Net Cash Per Share | $6.27 |
| Working Capital | $50.00K |
| Shareholder Equity | $50.00K |
| Book Value Per Share | $0.02 |
| Total Assets | $20.79M |
| Total Liabilities | $20.74M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$32.65M |
|---|---|
| FCF Per Share | -$10.15 |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -61.80% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -61.80% |
Dividends and Yields
PASG does not pay a dividend.
| Buyback Yield | -0.07% |
|---|---|
| Shareholder Yield | -0.07% |
Stock Splits
The last split was a 1-for-20 reverse split on Jul 14, 2025.
| Last Split Date | Jul 14, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PASG
What is PASG's market cap?
Passage Bio has a market cap of $13.29M.
How many shares of PASG are outstanding?
Passage Bio has 3.22M shares outstanding. The count is up 1.23% from a year earlier.
Does PASG pay a dividend?
No. Passage Bio does not pay a dividend.
How much debt does PASG have?
Passage Bio has $0 of total debt and $20.16M of cash and equivalents, a net cash position of $20.16M.
PASG pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors